Axsome starts ACCORD phase 3 trial of AXS-05 in Alzheimer’s agitation

 

• Axsome Therapeutics (NASDAQ:AXSM) initiates ACCORD (Assessing Clinical Outcomes in Alzheimer’s Disease Agitation) study, a Phase 3, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of AXS-05 in the treatment of Alzheimer’s disease agitation.
• AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity. There is currently no approved treatment for AD agitation.
• “Initiation of the ACCORD Phase 3 trial in Alzheimer’s disease agitation continues the expedited clinical development of AXS-05 for this serious condition. The potential for AXS-05, with its unique pharmacological profile, in this indication is supported by the positive results in our completed pivotal ADVANCE trial,” said Herriot Tabuteau, MD, CEO.
• No treatments are currently approved for Alzheimer’s disease agitation.
• Press Release
• https://seekingalpha.com/news/3648021-axsome-therapeutics-initiates-accord-phase-3-trial-of-axsminus-05-in-alzheimer-s-disease